Moclobemide versus tranylcypromine in the treatment of depression
| Autor: | E. Moll, L Rossel |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Psychiatric Status Rating Scales
Depressive Disorder Monoamine Oxidase Inhibitors Moclobemide Tranylcypromine Hamilton Rating Scale for Depression Blood Pressure Antidepressive Agents Psychiatry and Mental health Blood pressure Anesthesia Benzamides Endogenous depression Psychiatric status rating scales medicine Humans Psychology Depression (differential diagnoses) medicine.drug |
| Zdroj: | Acta Psychiatrica Scandinavica. 82:61-62 |
| ISSN: | 1600-0447 0001-690X |
| DOI: | 10.1111/j.1600-0447.1990.tb05333.x |
| Popis: | Moclobemide and tranylcypromine were compared in 2 randomized groups of 20 depressed patients each. Fifteen of the patients on moclobemide and 18 of those on tranylcypromine were diagnosed as suffering from endogenous depression. The dosage was 150-300 mg moclobemide and 15-30 mg tranylcypromine daily. At the end of treatment, improvement on the Hamilton Rating Scale for Depression was 59.3% in the moclobemide group and 65.5% in the tranylcypromine group. The final overall assessment of efficacy was good or very good for 68% of the patients on moclobemide and for 85% of those on tranylcypromine. The final assessment of tolerance was good or very good for 85% of the moclobemide patients and 100% of the tranylcypromine patients. None of the differences in scores between the groups were statistically significant. This study therefore yielded comparable results for efficacy and tolerance of the 2 drugs in the treatment of depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text